Skip to content

多西米蒂

US · DOCS #2122 按市值排名 上市于 2021
30.97 -0.53 -1.68%
实时 - 追踪5344个代码 - 心跳于179秒前 · 2026-10-16 19:30

✦ 量化合理价值 计算方式说明

接近合理价值
25.33 合理价值 ≈ 50.92 76.51
  • 基于该股自身过去5年平均市盈率乘以滚动每股收益,推算出的合理价值区间为25.33-76.51。
  • 当前价格比按平均倍数计算的合理价值(50.92)低39.2%。

估值 各估值倍数与自身5年区间的对比

市净率 5.44 低于历史水平 第23百分位
5年平均 13.58 · 在Health Information Services中排名第31/41
市盈率 33.30 低于历史水平 第15百分位
5年平均 51.96 · 前瞻 34.58 · 在Health Information Services中排名第4/17
市销率 7.60 低于历史水平 第13百分位
5年平均 17.18 · 前瞻 7.27 · 在Health Information Services中排名第33/42

同业对比 Health Information Services

公司 市值 市盈率(TTM) 市净率 股息率
多西米蒂 (DOCS) 5.52B 36.87 6.03 0.00%
Veeva Systems (VEEV) 50.25B 50.88 6.76 0.00%
BrightSpring Health Services (BTSG) 12.04B 36.89 5.88 0.00%
Tempus AI (TEM) 11.68B -44.94 26.24 0.00%
Hinge Health (HNGE) 8.00B 74.11 23.24 0.00%
HealthEquity (HQY) 7.61B 33.22 3.83 0.00%

StockVane 追踪范围内同行业的其他公司。

Morningstar

★★★☆☆ 合理价值36.73 经济护城河None 不确定性High

当前股价低于晨星合理价值估算18.6%。

合理价值

Given the significant price pressure over the last year, Doximity Inc might appear cheap. However, to account for the possibility that it may be a value trap, we've restricted its rating to 3 stars. The stock currently trades at a 22% discount to our quantitative fair value estimate of $36.73 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The firm's liquidity increases our fair value estimate. Adequate liquidity allows a company to meet short-term obligations, enhancing financial stability and reducing distress risk. For example, the firm's median trading volume over the past 60 days lies in the top 20% compared with peers globally. Trading volumes are high on shares, which may indicate increased institutional interest in stock ownership. We believe this is a sign that shares could be undervalued.

Alternatively, the firm's valuation metrics are potentially concerning. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's enterprise value to revenue ratio of 6.6, for example, ranks in the top 20% compared with peers globally. This overstates the long-term cash flow growth potential of the organization. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.

经济护城河

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

作者:Quantitative Equity Report

报价时间 2026-10-16 19:30:04 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

多西米蒂 讨论区 0 条评论

发表评论